A federal appeals court is hearing a closely watched case today that may have significant implications for the pharmaceutical industry, but especially for smaller drug makers.
The session hinges on a disputed interpretation of patent law, and the case is considered so important that all 12 judges on the US Court of Appeals for the Federal Circuit in Washington, D.C., are hearing arguments, which is an unusual occurrence.
Read Full Article »